tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MannKind price target raised to $7 from $6 at H.C. Wainwright

H.C. Wainwright analyst Oren Livnat raised the firm’s price target on MannKind (MNKD) to $7 from $6 and keeps a Buy rating on the shares post the Q4 results. The analyst says "rapid" Tyvaso DPI royalty growth brings "breakeven within sight" for the company. In addition, MannKind shares "should be backstopped by the ever-present prospect" of a bid from United Therapeutics (UTHR), the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on MNKD:

Disclaimer & DisclosureReport an Issue

1